XPAR
GNFT
Market cap789mUSD
Jul 10, Last price
13.74EUR
1D
-0.29%
1Q
58.29%
Jan 2017
-34.60%
IPO
9.29%
Name
Genfit SA
Chart & Performance
P/E
456.60
P/S
10.27
EPS
0.03
Div Yield, %
—
Shrs. gr., 5y
6.31%
Rev. gr., 5y
16.79%
Revenues
67m
+134.56%
Net income
2m
P
CFO
16m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Genfit S.A. functions as a late-stage biopharmaceutical enterprise, primarily dedicated to the identification and advancement of novel therapeutic drugs and diagnostic technologies for metabolic and liver-related conditions. A prominent candidate in its pipeline is Elafibranor, currently in Phase III clinical trials for treating primary biliary cholangitis. The company is also developing NIS4, a diagnostic platform aimed at identifying nonalcoholic steatohepatitis (NASH) and fibrosis. Its diverse portfolio further includes VS-01, designed for Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is undergoing Phase 1b/2a trials for cholangiocarcinoma (CCA); and a combination of VS-01-ACLF with Nitazoxanide (NTZ), in Phase 1 for acute-on-chronic liver failure. Additionally, Genfit is researching VS-02-HE in preclinical stages to reduce hyperammonemia and stabilize blood ammonia, alongside SRT-015, an ASK1 inhibitor engineered to suppress cellular apoptosis, inflammation, and fibrosis. Genfit has established strategic collaborations, notably a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. It also partnered with Genoscience Pharma to jointly develop and market the experimental treatment GNS561 for CCA. The company was founded in 1999 and is headquartered in Loos, France.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||